Moderna (MRNA) vs peers
MRNA's P/S is 43.9x, compared with 6.3x at the middle of 6 peers.
Biotechnology. Updated .
| Stock | P/S | Own 5-year rank |
|---|---|---|
| MRNAModerna | 43.9x | 100% |
| VRTXVertex Pharmaceuticals | 10.6x | 70% |
| ABBVAbbVie | 7.8x | 100% |
| GILDGilead Sciences | 6.3x | 98% |
| AMGNAmgen | 6.3x | 99% |
| REGNRegeneron Pharmaceuticals | 5.5x | 40% |
| INCYIncyte | 4.4x | 62% |
How to read this comparison
Up to eight covered companies in the same industry, largest market value first.
P/S divides the stock market value by revenue from the previous twelve months. The middle peer reading excludes MRNA and unavailable values.
Own 5-year rank compares each stock with its available weekly readings within the last five years. At least 26 usable weeks are required. A rank of 20% means its current multiple is above 20% of its past readings. It is not a rank against the other stocks in this table.
Dates show data updates; the latest available weekly observation can differ between stocks. Different growth rates, margins and financial risks can explain different multiples. Missing or non-positive denominators are left unranked.